| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1033217570 |
| P356 | DOI | 10.2165/00019053-199507050-00004 |
| P698 | PubMed publication ID | 10155327 |
| P2093 | author name string | Davey PG | |
| Parker SE | |||
| P2860 | cites work | Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? | Q28329301 |
| Audit of prescription and assay of aminoglycosides in a UK teaching hospital | Q70769444 | ||
| Initial aminoglycoside levels in the critically ill | Q71098846 | ||
| Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function | Q71135148 | ||
| Clinical experience with a method for adjusting gentamicin dose from measured drug clearance | Q71169111 | ||
| Bobbing oscillopsia from gentamicin toxicity | Q72110441 | ||
| Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro | Q72196470 | ||
| Once-daily aminoglycoside dosing | Q72209752 | ||
| Aminoglycoside monitoring in the once- or twice-daily era. The Dutch situation considered | Q72556345 | ||
| Survey of wastage from intravenous admixture in US hospitals | Q74822946 | ||
| Direct costs of intravenous delivery systems | Q74823036 | ||
| The toxic effect of streptomycin on the vestibular and cochlear apparatus; an experimental study on cats | Q75925359 | ||
| Ototoxicity of amikacin | Q28333609 | ||
| Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides | Q28361967 | ||
| Pharmacoeconomics of intravenous drug administration | Q33560218 | ||
| Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982 | Q34055509 | ||
| Determinants of efficacy and toxicity of aminoglycosides | Q34510814 | ||
| Increased aminoglycoside dosage requirements in hematologic malignancy | Q35253342 | ||
| First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. | Q36752618 | ||
| Cost of hospital antimicrobial chemotherapy. A method for global cost calculation | Q36980975 | ||
| Cost of gentamicin assays carried out by microbiology laboratories | Q37242427 | ||
| Therapeutic drug monitoring: improved performance through educational intervention | Q38060446 | ||
| Prospective audit of aminoglycoside usage in a general hospital with assessments of clinical processes and adverse clinical outcomes. | Q38950978 | ||
| Once versus thrice daily gentamicin in patients with serious infections | Q39369365 | ||
| Cost-effective choice of antimicrobial therapy for serious infections | Q39592533 | ||
| What price success? The continuing saga of the toxic:therapeutic ratio in the use of aminoglycoside antibiotics | Q39652048 | ||
| Drug-induced sudden hearing loss and vestibular disturbances | Q40323176 | ||
| Practicalities of once-daily aminoglycoside dosing | Q40664993 | ||
| Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients | Q40718971 | ||
| Severe rombergism due to gentamicin toxicity | Q41984847 | ||
| Risk Factors for Nephrotoxicity in Patients Treated with Aminoglycosides | Q42247725 | ||
| Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone | Q43459102 | ||
| Cost comparison of intravenous antibiotic administration | Q43662527 | ||
| Government liable for failure to monitor a patient's serum gentamicin concentration in an Army hospital | Q43936285 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Antibiotic Misuse in Two Clinical Situations: Positive Blood Culture and Administration of Aminoglycosides | Q46169845 | ||
| Serum level monitoring of aminoglycoside antibiotics. Limitations in intensive care unit-related bacterial pneumonia | Q47648271 | ||
| Cochlear and vestibular gentamicin toxicity. A clinical study of systemic and topical usage. | Q50632985 | ||
| Ototoxicity of Gentamicin in Man: A Survey and Controlled Analysis of Clinical Experience in the United States | Q50645402 | ||
| Cost containment associated with decreased parenteral antibiotic administration frequencies. | Q52686770 | ||
| Bacteremia due to Escherichia coli: a study of 861 episodes. | Q54312278 | ||
| Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. | Q54319060 | ||
| Effects of a restrictive antibiotic policy on clinical efficacy of antibiotics and susceptibility patterns of organisms. | Q54322087 | ||
| Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of t | Q64132922 | ||
| Pseudomonas Bacteremia: Pharmacologic and Other Bases for Failure of Treatment with Gentamicin | Q67238838 | ||
| Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis | Q67281381 | ||
| Once-daily aminoglycosides | Q67959309 | ||
| Antibiotic treatment for surgical peritonitis | Q68060935 | ||
| The chief scientist reports.... Implementation of research findings | Q68170953 | ||
| Human and non-financial costs of hospital-acquired infection | Q68315396 | ||
| Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections | Q68509565 | ||
| Aminoglycoside ototoxicity | Q68796326 | ||
| What is the cost of nephrotoxicity associated with aminoglycosides? | Q69462800 | ||
| A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections | Q69522572 | ||
| Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity | Q69561833 | ||
| Dosage of gentamicin and monitoring of blood levels: an action fails | Q69882389 | ||
| Once-daily dosing decreases renal accumulation of gentamicin and netilmicin | Q69936275 | ||
| Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia | Q70386358 | ||
| P433 | issue | 5 | |
| P921 | main subject | sepsis | Q183134 |
| Gram-negative bacteria | Q632006 | ||
| P304 | page(s) | 393-402 | |
| P577 | publication date | 1995-05-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Once-daily aminoglycoside administration in gram-negative sepsis. Economic and practical aspects | |
| P478 | volume | 7 |
| Q44041308 | Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients. |
| Q40675256 | Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections |
| Q33775991 | Minimisation of aminoglycoside toxicity in patients with cystic fibrosis |
| Q41138092 | Pharmacoeconomics: where is the link with pharmacokinetics and biopharmaceutics? |
| Q41470496 | Pharmacoeconomics: where is the link with pharmacokinetics and biopharmaceutics? |
| Q42537036 | Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules |
Search more.